AI Proteins, a Boston, MA-based biotechnology company using artificial intelligence to design synthetic proteins de novo, announced its public launch and closed an oversubscribed $18.2 million in seed funding round co-led by Cobro Ventures and Lightchain Capital.
AI Proteins has built the first high-throughput platform that can design entirely synthetic proteins from scratch (“de novo”), giving engineers an unprecedented amount of control over protein function and properties.
“After a decade in academia, de novo protein design is finally ready for prime time,” says AI Proteins founder, President, and CSO Dr. Chris Bahl. “With this technology, we will be able to bring next-generation therapeutics to the clinic faster.”
Drew Dennison, AI Proteins CEO and Managing Director of Lightchain Capital, said: “The AI Proteins platform is surrounded by all the right ingredients to drive success—a terrific and incredibly talented team, a dedicated group of investors with a deep commitment to the company, and an outstanding culture.
AI Proteins is using its de novo protein design platform to unlock the therapeutic potential of miniproteins, which are peptides that form a hyper stable three-dimensional structure.
Company: AI Proteins, Inc.
Round: Seed Round
Funding Month: November 2022
Lead Investors: Cobro Ventures and Lightchain Capital
Company Website: https://aiproteins.bio/
Software Category: High-Throughput Drug Discovery platform
About the Company: AI Proteins is re-imagining protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that can be optimized for oral delivery.